Validation of comprehensive genomic profiling for prognostic and potential therapeutic molecular classification of endometrial cancer
Open Access
- 11 August 2025
- journal article
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 35 (10) , 102107
Abstract
No abstract availableKeywords
Funding Information
- Foundation Medicine Inc
This publication has 30 references indexed in Scilit:
- Performance of molecular classification in predicting oncologic outcomes of fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancerInternational Journal of Gynecological Cancer, 2024
- 37MO Dostarlimab plus chemotherapy in primary advanced or recurrent endometrial cancer (pA/rEC) in the RUBY trial: Overall survival (OS) by MMR status and molecular subgroupsESMO Open, 2024
- Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO studyGynecologic Oncology, 2024
- Characterization of mismatch‐repair/microsatellite instability‐discordant endometrial cancersCancer, 2023
- FIGO staging of endometrial cancer: 2023International Journal of Gynecology & Obstetrics, 2023
- Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- Analysis of a Real-World Progression Variable and Related Endpoints for Patients with Five Different Cancer TypesAdvances in Therapy, 2022
- Diagnosis and management of a recurrent polymerase-epsilon (POLE)-mutated endometrial cancerGynecologic Oncology, 2019
- Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non–Small Cell Lung Cancer Using a Clinicogenomic DatabaseJAMA, 2019
- Confirmation of ProMisE: A simple, genomics‐based clinical classifier for endometrial cancerCancer, 2017